# DiviTum<sup>®</sup> TKa **TEST RESULTS**

## **FINAL REPORT**

Laboratory director:

Order by


# Page: I of I

## Patient name: Profile 3

Date of birth :	Sex:	Patient ID:
MM /DD/YYYY	F	
Notes:		
Pati	ent sample in	formation
Ordered:	I	2/01/2022
Collected:	0	5/31/2023 12:00 PM
Туре:	S	erum
Reported :		
Sample ID:		
Institution sample ID	:	

(	Order by:								
	Report recipient :		Contact info:						
(	History of test results								
	DiviTum <sup>®</sup> Units of Activity (DuA) Reference range : < 250 DuA								
	04/20/2023	724	12/15/2022	329					
	03/23/2023	685	12/01/2022	618					
	02/23/2023	638							
	01/26/2023	501							
	01/12/2023	296							
	12/29/2022	487							

#### Thymidine Kinase activity (TKa)



\* < 145 DuA for patients treated with CDK4/6 inhibitor .23

#### General test information:

- TKa values are associated with disease progression within 30 days or 60 days from sampling TKa values < 250 DuA are associated with decreased likelihood of disease progression within the next 30 days or 60 days post testing (81% and 82% specificity, respectively) TKa values < 250 DuA have negative predictive values for disease progression of 97% and 94% for 30 days or 60 days, respectively, post-testing progression free survival (PFS ) Testing for TKa should be used in conjunction with other clinical methods used for monitoring methods in breast concept patients.

- DiviTum TKa is not in divide a stand alone test to determine the outcome of disease nor to suggest
  DiviTum TKa is not for "serial testing" because the test result at a given time point does not compare to the test result at previous time point, but to a fixed cutoff value
  DiviTum TKa is not indicated as a stand-alone test to determine the outcome of disease nor to suggest or infer an individual patient's likely benefit from therapy

#### Limitations:

- The DiviTum TKa test has been validated for use only with serum samples from postmenopausal women previously diagnosed with HR + metastatic breast cancer
   Accurate results are dependent on following the proper sample collection, storage, and handling
- Procedures
   Patients who have high levels of triglycerides may show falsely elevated TKa values when tested, and who have high levels of bilirubin (conjugated) may show falsely depressed TKa values when tested with DiviTum TKa
- Patients who are taking cisplatin may show falsely depressed TKa values when tested with DiviTum TKa
  The effects of chemotherapy on DiviTum TKa have not yet been fully evaluated

References I. Paoletti C, Barlow WE, Cobain E, et al.Evaluating serum thymidine kinase I in patients with hormone receptor-positive metastatic breast cancer receiving first-line endocrine therapy in the SWOG S0226 trial. Clin Cancer Res. 2021;27 (22):6115-6123.2. Malorni L, De Laurentiis M, Bianchini G, et al. Serum thymidine kinase I activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2–) advanced breast cancer (aBC) treated in first line with ribociclib and letrozole in the BiotaLEE trial. Poster presented at: European Society for Medical Oncology (ESMO) Congress (held virtually ); September 16-21, 2021. 3. Malorni L, Tyekucheva S, Hilbers FS, et al; International Breast Cancer study Group; Breast International Group and PYTHIA Collaborators. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2 -negative metastatic breast cancer treated with palbociclib and letvestrant. Eur J Cancer. 2022;164:39-51. 4. US Food and Drug Administration. July 2022 510(K) Clearances. US Food and Drug Administration website. https://www.accessdata.fda.gov/cdrh\_docs/pdf20/K202852.pdf. Published July 29, 2022. Accessed March 1, 2023.5. Bergqvist M, Nordmark A, Williams A, et al. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Biomarkers. 2023 to 1000 S0226). Biomarkers. 2023

DiviTum TKa has been cleared by the US FDA. Biovica is certified under CLIA to perform high complexity clinical laboratory testing. The test may be covered by one or more US pending or issued patents-see www.biovica.com for details DiviTum® is a registered trademark of Biovica International AB

©2023 Biovica, Inc. All rights reserved. BDT1002 March 2023



6195 CornerstoneCourtE, Suite 101 San Diego, CA 92121 Main line: 858-230-6164

www.biovica.com